SYRE Q1 2023 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$198,000-85.5% YoY

Gross Profit

-$350,000-176.8% margin

Operating Income

-$19M-9498.0% margin

Net Income

-$18M-9304.0% margin

EPS (Diluted)

$-4.89

QoQ Revenue Growth

+17.9%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$52M

Total Liabilities

$19M

Stockholders' Equity

$34M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$198,000	$1M	-85.5%
Gross Profit	-$350,000	$865,000	-140.5%
Operating Income	-$19M	-$24M	+23.1%
Net Income	-$18M	-$24M	+24.6%